
BSX • NYSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold BSX in your mock portfolio yet.
A PE ratio of 52.21 and EPS of 1.87 suggest investors are paying a premium for Boston Scientific’s earnings, implying expectations of continued growth. However, without explicit revenue and margin trends, the valuation looks rich relative to current earnings, making the risk/reward more balanced than clearly attractive. The market appears to be pricing in strong future profitability, leaving less room for error.
The stock is trading at $97.64, up 5.9% over the last month, but still below its 200-day moving average of $100.81, signaling it is in a mild intermediate-term downtrend. An RSI of 34.44 is close to oversold territory, suggesting selling pressure has been elevated but may be stabilizing. Overall, price action and technicals point to a consolidating name with a mixed near-term technical outlook.
Website traffic at roughly 598k visitors per month indicates a solid digital footprint, but no growth trend is provided to infer acceleration or deceleration. Job openings at 971, down 2.9% month over month, may signal modest hiring discipline or a slight cooling in expansion plans, but not a sharp contraction. Social media metrics are mixed to mildly positive, with small follower gains on Facebook and LinkedIn and a slight decline on Twitter/X, suggesting stable but not explosive engagement.
Boston Scientific’s stock reflects a premium valuation with expectations of continued growth, but the technical setup and alternative data currently point to a more balanced outlook. The price sits below its 200-day moving average with an RSI near oversold, suggesting a consolidating phase rather than a clear trend. Overall, the combination of rich valuation, mixed technicals, and steady but unspectacular alternative data supports a neutral view at this time.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: